In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia.
Intravenous delivery of apolipoprotein B-specific siRNA with a sixth-generation of dendritic poly(L-lysine) (KG6) resulted in siRNA-mediated knockdown of ApoB in healthy C57BL/6 mice without hepatotoxicity, and with a significant reduction of serum low-density lipoprotein cholesterol in apolipoprotein E-deficient mice.